Overall market sentiment has been high on Tyme Technologies Inc (TYME) stock lately. TYME receives a Bullish rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.
InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.
Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .
What's Happening With TYME Stock Today?
Tyme Technologies Inc (TYME) stock is trading at $1.88 as of 12:04 PM on Tuesday, Jan 26, a drop of -$0.12, or -6.05% from the previous closing price of $2.00. The stock has traded between $1.86 and $2.04 so far today. Volume today is low. So far 1,087,960 shares have traded compared to average volume of 2,084,944 shares.
To see InvestorsObserver's Sentiment Score for Tyme Technologies Inc click here.
More About Tyme Technologies Inc
Tyme Technologies Inc is the U.S based clinical-stage biotechnology company. The company is focused on the development and commercialization of targeted cancer therapeutics with a broad range of oncology indications for humans. SM 88, its proprietary drug candidate compound, is a novel compound that has the potential to alter defenses to oxidative stress and increase free radical availability to the cancer cell. The company is currently conducting a Phase II trial in prostate cancer.
Click Here to get the full Stock Score Report on Tyme Technologies Inc (TYME) Stock.
